MBX Biosciences, Inc. Common Stock (MBX) Fair Value & Analysis
Healthcare · US · Market cap $3.3B · ISIN US55287L1017
What is MBX Biosciences, Inc. Common Stock really worth?
MBX Biosciences, Inc. Common Stock
MBX · US
Below-average quality, and trading another 713% above our fair value of $7.59.
As of Aug 19, 2026, the fair value of MBX Biosciences, Inc. Common Stock is $7.59 per share against a price of $61.72, so the fair value sits 88% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 19, 2026
From 1 valuation models · updated 18 days ago
Fair value updated Aug 19, 2026, revised from $7.68 to $7.59 (−1.2%) since Aug 13, 2026. Share price −8.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($9.49). The favourable scenario is already priced in.
- Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($5.01 to $9.49) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
24‑month range $5.79 – $70.70 · fair‑value band $5.01 – $9.49 · the $61.72 price screens above the $7.59 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
MBX Biosciences, Inc. Common Stock (MBX) currently trades at $61.72, while our model-based Fair Value estimate is $7.59, implying the stock looks roughly 713.0% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
It earns a return on equity of −25.7%. The balance sheet holds a net cash position of $74.7M. Fundamentals as of Aug 19, 2026
Our scenario range runs from $5.01 (bear case) to $9.49 (bull case); at $61.72, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −88%, MBX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when MBX reaches fair value
Put MBX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Full company description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
MBX Biosciences, Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$87.0M in FY2025.
MBX screens 713% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare MBX Biosciences, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is MBX Biosciences, Inc. Common Stock (MBX) overvalued or undervalued?
What is the fair value of MBX?
What is the quality score of MBX?
What is the price target for MBX Biosciences, Inc. Common Stock (MBX)?
What is the MBX Biosciences, Inc. Common Stock stock forecast for 2026?
What is the net profit margin of MBX?
Watch MBX Biosciences, Inc. Common Stock in the live analysis
One click puts MBX Biosciences, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.